RB1
13 abstracts
Abstract
Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.Org: Puma Biotechnology Inc.,
Abstract
Investigation of leptomeningeal disease in high grade glioma and characterization of molecular alterations.Org: Caris Life Sciences, Irving, TX, Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Levine Cancer Institute,
Abstract
Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center,
Abstract
Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes.Org: University of California Irvine School of Medicine, Barbara Ann Karmanos Cancer Institute, Lombardi Comprehensive Cancer Center, Caris Life Sciences, Irving, TX, Montefiore Einstein Center for Cancer Care,
Abstract
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Tempus Labs, Inc., David Geffen School of Medicine UCLA, Ohio State University Comprehensive Cancer Center,
Abstract
Evolution of genomic profiles in primary and recurrent brain gliomas.Org: Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, Center of Oncocytogenomics, Intitute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague 2, Czech Republic, Center of Oncocytogenomics, Institute of medical Biochemistry and Laboratory Diagnostics,General University Hospital and 1st Faculty of Medicine, Charles Unive, Prague, Czech Republic, Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles Unive, Praha 2, Czech Republic, Institute of Hematology and Blood Transfusion, Prague, Czech Republic, Department of Neurosurgery and Neurooncology, First Faculty of Medicine of Charles University and Military University Hospital Prague, Prague, Czech Republic,
Abstract
A multi-center natural history study of precision-based genomics in prostate cancer (PC).Org: Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Memorial Sloan Kettering Cancer Center, University of California San Diego,
Abstract
Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non-muscle invasive bladder cancer: A prospective study.Org: H. Lee Moffitt Cancer Center and Research Institute, Predicine, Inc., Predicine Inc., Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute,
Abstract
Next generation sequencing reveals targetable mutations in multiple sarcoma histologies.Org: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Vander Ingram Cancer Center, Division of Epidemiology and Community Health,
Abstract
Relations between mutant KRAS and TP53 subtypes and other co-mutations in pancreatic cancer.Org: Bridgeport Hospital, Yale New Haven Health, University of Pittsburgh, School of Medicine, Yale University Dept of Pathology, Yale University,
Abstract
Mutation profiling of gliomas based on sex, age, and family history.Org: Shenzhen Longgang Third People's Hospital, Shenzhen, China, Haplox biotechnology Co., Ltd., Shenzhen, Guangdong, China, HaploX Biottechnology Co., Ltd., Shenzhen, Guangdong, China, HaploX Biotechnology, Shenzhen, China, HaploX Biotechnology Co., Ltd, Shenzhen, Guangdong, China, Tianjin Union Medical Center, Tianjin, Tianjin, China, Shenzhen, Guangdong, China, HaploX Biotechnology, Shenzhen, China,
Abstract
Spectrum of germline pathogenic variants among patients with cancer in Mexico.Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico, National Institute of Medical Sciences and Nutrition Salvador Zubirán, City of Hope National Medical Center, Latin American School of Oncology,
Abstract
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: The IMMINENT study.Org: University of Verona, Oncology Section, Azienda Ospedaliera Universitaria Integrata di Verona, Ospedale San Bortolo Azienda ULSS8 Berica - Distretto Est, Santa Chiara Hospital, Trento, Italy, Policlinico Universitario Gaspare Rodolico,